Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QRL-101 pharmacodynamics in healthy volunteers
NCT06681441Phase 1Completed
- Sponsor
- QurAlis
- Start
- Oct 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of QRL-101 in amyotrophic lateral sclerosis (ALS) and epilepsy (6 arms), sponsored by QurAlis. Primary endpoints: Single pulse TMS-EMG motor evoked potential amplitude at Day 1 and mNETT strength-duration time constant at Day 1. Started Oct 2024; status: completed.
02
Drugs
QRL-101
03
Conditions
amyotrophic lateral sclerosis (ALS)epilepsy
Beyond the preview
Go deeper on NCT06681441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06681441.